Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St